Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to name a new CEO by March 2023
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(218)
•••
Comment by itntdfon Feb 08, 2023 3:37pm
115 Views
Post# 35275357

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023those answers are plausible but they were not part of the explanation about which i took issue.

whomever were to take out oncy would already have some type of agreement with AN, whether or not it would make sense to reduce it to a formal partnership would be up to the buyer.

how much $ is "retaking" 20% of the world's population re: the use of pela for any and all approved indications in AN's exclusive territory worth?

imo, i don't see AN walking away for a pittance.  don't know how many shares they might have if they were to exercise their warrants, but if there were a buyout my guess is those shares would be worth way more than what AN has in this deal as of now.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities